Pulmonary Disease Doctors in Jefferson Hills, PA Accepting Medicare

4 Pulmonary Disease doctors found. Showing 1 - 4

Paul David Laman Jr., MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1200 Brooks Ln, Suite 130, Jefferson Hills, PA 15025 Phone: 412-469-3600    Fax: 412-469-3630

Toni Sicenica, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Brooks Ln, Suite 130, Jefferson Hills, PA 15025 Phone: 412-469-3600    Fax: 412-469-3630

Michael B Fashho, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 565 Coal Valley Rd, Jefferson Hills, PA 15025 Phone: 412-469-5000

Emil A Deliere, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1200 Brooks Ln, Suite 130, Jefferson Hills, PA 15025 Phone: 412-469-3600    Fax: 412-469-3630

News Archive

HHS offers progress report on shrinking Medicare's doughnut hole

A provision in the health law was intended to help fill a gap in Medicare's prescription drug coverage. On Thursday, administration officials said 3.6 million beneficiaries saved $2.1 billion on prescription drugs in 2011.

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Pharmaceuticals Corporation in the U.S. District Court of the District of Massachusetts.

Australia, Fiji establish coalition to address impact of HIV/AIDS on business

The Fiji Australia Business Council and UNAIDS on Monday agreed to a partnership under which they will develop a business coalition in Fiji to strengthen the private sector's response to HIV/AIDS, the Fiji Times reports (Fiji Times, 7/22).

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.

Read more Medical News

› Verified 2 days ago